151-165 of 334
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
NeuroFrontiersSafety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiersNew-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
Charles Turck, PharmD, BCPS, BCCCP
John Brandsema, MD
Closing Care Gaps and Addressing Unmet Needs in SMA
NeuroFrontiersClosing Care Gaps and Addressing Unmet Needs in SMA
Jennifer Kwon, MD
Examining Care Collaborations for Patients with SMA
NeuroFrontiersExamining Care Collaborations for Patients with SMA
Andrew Wilner, MD, FACP, FAAN
Nassim Rad, MD
Vanessa Battista, RN
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Heart MattersTimely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Kevin Alexander, MD
- advertisement
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Heart MattersEquitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Kevin Alexander, MD
Assessing Adverse Pregnancy Outcomes in Isolated Sjögren’s Disease
Living RheumAssessing Adverse Pregnancy Outcomes in Isolated Sjögren’s Disease
Marlene Mimi Maeusli, PhD.
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Reframing Sjögren’s Syndrome: Insights from a Comprehensive Review
Living RheumReframing Sjögren’s Syndrome: Insights from a Comprehensive Review
Efgartigimod Shows Early Promise for Primary Sjögren’s Disease
Living RheumEfgartigimod Shows Early Promise for Primary Sjögren’s Disease
Unmasking Patient Subtypes in Sjögren’s Disease to Enable Personalized Care
Living RheumUnmasking Patient Subtypes in Sjögren’s Disease to Enable Personalized Care
- advertisement
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Heart MattersTranslating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Heart MattersStaging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Heart MattersAnalyzing Outpatient Worsening Heart Failure in ATTR-CM
